English Korean Chinese
ホーム > 市場調査レポート > 医薬品 > 製薬企業関連 > 医薬品市場の動向‐2008〜2012年の市場予測と成長機会:第3版
カテゴリ
医薬品 (4964)
OTC (153)
がん (943)
ドラッグデリバリー (185)
ワクチン (181)
感染症 (353)
規制環境 (132)
後発医薬品 (135)
骨疾患 (37)
処方薬 (158)
神経疾患 (174)
精神疾患 (89)
製薬企業関連 (531)
創薬 (1524)
糖尿病 (193)
動物用医薬 (17)
肥満症 (44)
市場調査レポート

医薬品市場の動向‐2008〜2012年の市場予測と成長機会:第3版

Pharmaceutical Market Trends, 2008 - 2012: Key market forecasts and growth opportunities (3rd edition)

発行 Urch Publishing, Ltd.
出版日 2008年11月 商品コード 76406
ページ情報 英文 142 Pages
価格
US$ 2,120 換算 ¥ 170,808 (税抜) PDF by E-mail (Single User License)
US$ 2,150 換算 ¥ 173,225 (税抜) Hard Copy
US$ 12,275 換算 ¥ 988,996 (税抜) PDF by E-mail (Companywide user License)


原文目次

Abstract

"The global pharmaceutical market grew to US$712 billion in 2007, growing at a compound annual growth rate (CAGR) of 10.0% between 1999 and 2007. Year-on-year growth in the global pharmaceutical market increased to 10.7% in 2007, largely as a result of strong sales growth for new innovative products and high market growth in emerging pharmaceutical markets such as China."

2008 updated version of this best-selling report!

Pharmaceutical Market Trends, 2008 - 2012: Key market forecasts & growth opportunities presents a detailed trend analysis of the global pharmaceutical market as at the end of 2006 and forecasts until 2012. The 142 page report presents a series of market forecasts and growth opportunities in order to help inform pharmaceutical decision-making, particularly in the areas of corporate planning, portfolio management and market forecasting.

The data and analysis contained within the report are comprehensive, consistent and up-to-date in order to provide a single-point reference for understanding key pharmaceutical market trends in 2008.

KEY FINDINGS INCLUDE

  • The global pharmaceutical market is forecast to grow to US$929 billion in 2012, an equivalent compound annual growth rate (CAGR) of 5.5% over the next five years.
  • In 2007 the leading therapy areas by sales were CNS with 16.5% share and cardiovascular with 15.4%.
  • Four of the top 10 products in 2007 are forecast to increase sales over the next five years.
  • The US retail pharmaceutical market grew to US$206 billion but growth rates fell due to loss of patent protection on some blockbusters
  • France, Germany and the UK together accounted for almost 50% of all European pharmaceutical sales in 2007.
  • TThe top 100 blockbuster drugs generated sales of US$252.5 billion, accounting for 35.5% of the total pharmaceutical market.
  • The leading blockbuster by increased sales revenues in 2007 was the blood agent product Plavix (clopidogrel bisulfate), marketed by Sanofi-Aventis and Bristol-Myers Squibb.
  • There were a total of 61 companies generating pharmaceutical sales in excess of US$1 billion in 2007

KEY FEATURES OF THE REPORT

  • Comprehensive market trends for key countries, regions , therapy areas, products and companies.
  • Country profiles for leading pharma markets with market segment trends and 5 year forecasts.
  • Therapy area profiles for leading therapeutic classes and key products and 2012 sales forecasts.
  • Detailed profiles of 10 leading pharmaceutical products in 2008, including five year future sales forecasts.
  • Detailed profiles of 10 leading pharmaceutical companies in 2008, including 2012 sales forecasts.(AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson and Johnson, Merck & Co, Novartis, Pfizer, Roche, Sanofi-Aventis Wyeth)

USE THIS REPORT TO:

  • 1. Quickly gain an overview into the global pharmaceutical market and its major companies and products.
  • 2. Identify key areas of pharmaceutical market growth and key opportunities for delivering successful sales growth over the next five years.
  • 3. Support internal planning and decision-making with an external perspective founded on detailed analysis and transparent market forecasts.

REPORT COVERAGE

The report methodology provides a detailed but transparent analysis of key pharmaceutical market trends, including key markets, therapy areas, products and companies. Historical trends are formed over a three-year time horizon and future forecasts are made using a five-year future time period. Thus, the data and analysis relate to the nine-year time horizon from 2005 to 2012.

All data used in outlining historical trends is clearly sourced within the report and any data limitations or additional assumptions are explicitly detailed within the text of the report. Future market forecasts are projected based on both historical trends and future expectations over market conditions and events. The assumptions used to form the basis of key market forecasts are outlined in detail within the text of the report.

Table of Contents

Executive Summary

  • Introduction
  • Key global markets
  • Key therapeutic markets
  • Key products
  • Key companies
  • Key trends and opportunities

Chapter 1 Introduction

  • Global pharmaceutical market
  • Report overview
    • Methodology
    • Sources
    • Structure

Chapter 2 Key global markets

  • Key pharmaceutical markets
  • US pharmaceutical market
    • US purchasing channels
    • US retail drug market
    • US market leaders
  • European pharmaceutical market
    • European retail drug market
  • Japanese pharmaceutical market

Chapter 3 Key therapeutic markets

  • Key therapy areas
    • Key product classes
  • CNS therapy area
    • CNS blockbusters
  • Cardiovascular therapy area
    • Cardiovascular blockbusters
  • Alimentary/metabolism therapy area
    • Alimentary/metabolism blockbusters
  • Anti-infectives therapy area
    • Anti-infectives blockbusters
  • Respiratory therapy area
    • Respiratory blockbusters
  • Oncologics therapy area
    • Antineoplastics/immunomodulator blockbusters

Chapter 4 Key products

  • Leading products
    • Lipitor (atorvastatin)
    • Plavix (clopidogrel)
    • Advair/Seretide (fluticasone/salmeterol)
    • Enbrel (etanercept)
    • Nexium (esomeprazole)
    • Remicade (infliximab)
    • Diovan/Co-Diovan/Provas/Miten (valsartan/hydrochlorothiazide)
    • Zyprexa (olanzapine)
    • Rituxan (rituximab)
    • Risperdal (risperidone)
  • Blockbuster trends
    • Blockbusters by drug type
    • Blockbusters by therapy area
    • Blockbusters by company

Chapter 5 Key companies

  • Major pharmaceutical companies
    • Major company financials
    • Major company locations
  • Top 10 pharmaceutical companies
  • Top 10 company financials
  • Top 10 company value drivers
  • Leading pharmaceutical companies
    • Pfizer
    • GlaxoSmithKline
    • Sanofi-Aventis
    • Roche
    • AstraZeneca
    • Novartis
    • Johnson and Johnson
    • Merck & Co
    • Wyeth
    • Eli Lilly

Chapter 6 Key trends and opportunities

  • Global market forecasts
    • The US market
    • The European market
    • The Japanese market
    • Other markets
  • Key therapy area forecasts
    • CNS market
    • Cardiovascular market
    • Alimentary/metabolism market
    • Anti-infectives market
    • Respiratory market
    • Oncologics market
  • Key product forecasts
    • Lipitor (atorvastatin)
    • Plavix (clopidogrel)
    • Advair/Seretide (fluticasone/salmeterol)
    • Enbrel (etanercept)
    • Nexium (esomeprazole)
    • Remicade (infliximab)
    • Diovan/Co-Diovan (valsartan/hydrochlorothiazide)
    • Zyprexa (olanzapine)
    • Rituxan (rituximab)
    • Risperdal (risperidone)
  • Key company forecasts
    • Pfizer
    • GlaxoSmithKline
    • Sanofi-Aventis
    • Roche
    • AstraZeneca
    • Novartis
    • Johnson and Johnson
    • Merck & Co
    • Wyeth
    • Eli Lilly

Appendix

  • Proprietary data sources
    • Product Trends Database
    • Company Trends Database
  • Top 117 pharmaceutical products
  • Top 61 pharmaceutical companies

LIST OF FIGURES

  • Figure 1: Global pharmaceutical market, 1999-2007
  • Figure 2: Report structure
  • Figure 3: Global pharmaceutical market share by region, 2007
  • Figure 4: Global pharmaceutical market by region, 2003-2007
  • Figure 5: US pharmaceutical market, 2003-2007
  • Figure 6: US pharmaceutical market share by purchasing channel, 2007
  • Figure 7: US pharmaceutical market by purchasing channel, 2003-2007
  • Figure 8: US retail pharmaceutical market, 2003-2007
  • Figure 11: Top 10 products by US pharmaceutical sales, 2007
  • Figure 12: Top 10 companies by US pharmaceutical sales, 2007
  • Figure 13: Top 10 companies by share of US pharmaceutical sales, 2007
  • Figure 14: European pharmaceutical market, 2003-2007
  • Figure 15: European pharmaceutical market share by country, 2007
  • Figure 16: European top 5 retail pharmaceutical market, 2003-2007
  • Figure 17: European top 5 retail pharmaceutical market share by country, 2007
  • Figure 18: European top 5 retail pharmaceutical market by country, 2003-2007
  • Figure 21: Japanese pharmaceutical market, 2003-2007
  • Figure 24: Global pharmaceutical market by therapy area, 2007
  • Figure 25: Top 10 product classes by global pharmaceutical sales, 2007
  • Figure 31: CNS pharmaceutical market, 2005-2007
  • Figure 28: Cardiovascular pharmaceutical market, 2005-2007
  • Figure 34: Alimentary/metabolism pharmaceutical market, 2005-2007
  • Figure 40: Anti-infectives pharmaceutical market, 2005-2007
  • Figure 37: Respiratory pharmaceutical market, 2005-2007
  • Figure 46: Oncologics pharmaceutical market, 2005-2007
  • Figure 49: Blockbuster drug sales share by drug type, 2007
  • Figure 50: Blockbuster drug sales share by lifecycle stage, 2007
  • Figure 51: Blockbuster drug sales share by therapy area, 2007
  • Figure 52: Blockbuster drug sales share by company, 2007
  • Figure 53: Major companies pharmaceutical sales, 2003-2007
  • Figure 54: Major companies revenue share allocation, 2007
  • Figure 55: Major companies revenue allocation, 2003-2007
  • Figure 56: Major companies pharmaceutical sales by location, 2007
  • Figure 57: Top 10 pharma companies pharmaceutical sales, 2003-2007
  • Figure 58: Top 10 pharma companies by global pharmaceutical sales, 2007
  • Figure 59: Top 10 biotechnology companies by global revenues, 2007
  • Figure 60: Top 10 pharma companies revenue share allocation, 2007
  • Figure 61: Top 10 pharma companies revenue allocation, 2003-2007
  • Figure 62: Key value drivers for top 10 pharma companies (income), 2007
  • Figure 63: Key value drivers for top 10 pharma companies (sales), 2007
  • Figure 64: Key value drivers for top 10 pharma companies (sales/R&D), 2007
  • Figure 65: Pfizer therapy area sales, 2003-2007
  • Figure 66: GlaxoSmithKline therapy area sales, 2003-2007
  • Figure 67: Sanofi-Aventis blockbuster therapy area sales, 2003-2007
  • Figure 68: Roche therapy area sales, 2003-2007
  • Figure 69: AstraZeneca therapy area sales, 2003-2007
  • Figure 70: Johnson and Johnson blockbuster therapy area sales, 2003-2007
  • Figure 71: Novartis therapy area sales, 2003-2007
  • Figure 72: Merck & Co blockbuster therapy area sales, 2003-2007
  • Figure 73: Wyeth blockbuster therapy area sales, 2003-2007
  • Figure 74: Eli Lilly therapy area sales, 2003-2007
  • Figure 75: Global pharmaceutical market forecast, 2003-2012
  • Figure 76: Global pharmaceutical market forecast by regions, 2003-2012
  • Figure 77: Top 10 pharmaceutical drugs by forecast sales, 2012
  • Figure 78: Lipitor (atorvastatin) forecast sales, 2003-2012
  • Figure 80: Plavix (clopidogrel) forecast sales, 2003-2012
  • Figure 79: Advair/Seretide (fluticasone/salmeterol) forecast sales, 2003-2012
  • Figure 83: Enbrel (etanercept) forecast sales, 2003-2012
  • Figure 82: Nexium (esomeprazole) forecast sales, 2003-2012
  • Figure 84: Remicade (infliximab) forecast sales, 2003-2012
  • Figure 87: Diovan/Co-Diovan (valsartan/hydrochlorothiazide) forecast sales, 2003-2012
  • Figure 85: Zyprexa (olanzapine) forecast sales, 2003-2012
  • Figure 81: Rituxan (rituximab) forecast sales, 2003-2012
  • Figure 86: Risperdal (risperidone) forecast sales, 2003-2012

LIST OF TABLES

  • Table 1: Global pharmaceutical market trends by region, 2005-2007
  • Table 2: US pharmaceutical market trends by purchasing channel, 2005-2007
  • Table 4: Top 10 products trends by US pharmaceutical sales, 2005-2007
  • Table 5: European top 5 retail pharmaceutical market trends by country, 2005-2007
  • Table 1: Global pharmaceutical market trends by therapy area, 2005-2007
  • Table 8: Top 10 product classes trends by global pharmaceutical sales, 2005-2007
  • Table 13: CNS blockbuster drug sales, 2005-2007
  • Table 11: Cardiovascular blockbuster drug sales, 2005-2007
  • Table 15: Alimentary/metabolism blockbuster drug sales, 2005-2007
  • Table 19: Anti-infectives blockbuster drug sales, 2005-2007
  • Table 17: Respiratory blockbuster drug sales, 2005-2007
  • Table 23: Cytostatics blockbuster drug sales, 2005-2007
  • Table 24: Top 20 products by global pharmaceutical sales, 2005-2007
  • Table 25: Lipitor (atorvastatin) profile, 2007
  • Table 26: Plavix (clopidogrel) profile, 2007
  • Table 27: Advair/Seretide (fluticasone/salmeterol) profile, 2007
  • Table 28: Enbrel (etanercept) profile, 2007
  • Table 29: Nexium (esomeprazole) profile, 2007
  • Table 30: Remicade (infliximab) profile, 2007
  • Table 31: Diovan/Co-Diovan/Provas/Miten (valsartan/hydrochlorothiazide) profile, 2007
  • Table 32: Zyprexa (olanzapine) profile, 2007
  • Table 33: Rituxan (rituximab) profile, 2007
  • Table 34: Risperdal (risperidone) profile, 2007
  • Table 35: Top 10 blockbuster products by global pharmaceutical sales growth, 2005-2007
  • Table 36: Top 10 blockbuster products by declining global pharmaceutical sales, 2005-2007
  • Table 37: New blockbuster products, 2005-2007
  • Table 38: Major companies revenue allocation trends, 2005-2007
  • Table 39: Top 10 pharma companies by global pharmaceutical sales, 2005-2007
  • Table 40: Top 10 biotechnology companies by global revenues, 2005-2007
  • Table 41: Top 10 pharma companies revenue allocation trends, 2005-2007
  • Table 42: Pfizer profile, 2007
  • Table 43: Pfizer blockbuster sales, 2005-2007
  • Table 44: GlaxoSmithKline profile, 2007
  • Table 45: GlaxoSmithKline blockbuster sales, 2005-2007
  • Table 46: Sanofi-Aventis profile, 2007
  • Table 47: Sanofi-Aventis blockbuster sales, 2005-2007
  • Table 48: Roche profile, 2007
  • Table 49: Roche blockbuster sales, 2005-2007
  • Table 50: AstraZeneca profile, 2007
  • Table 51: AstraZeneca blockbuster sales, 2005-2007
  • Table 52: Johnson and Johnson profile, 2007
  • Table 53: Johnson and Johnson blockbuster sales, 2005-2007
  • Table 54: Novartis profile, 2007
  • Table 55: Novartis blockbuster sales, 2005-2007
  • Table 56: Merck & Co profile, 2007
  • Table 57: Merck & Co blockbuster sales, 2005-2007
  • Table 58: Wyeth profile, 2007
  • Table 59: Wyeth blockbuster sales, 2005-2007
  • Table 60: Eli Lilly profile, 2007
  • Table 61: Eli Lilly blockbuster sales, 2005-2007
  • Table 62: Global pharmaceutical market forecast by regions, 2003-2012
  • Table 63: Global pharmaceutical market forecast by therapy area, 2007-2012
  • Table 64: Top 10 pharmaceutical drugs forecast, 2003-2012
  • Table 65: Top 10 pharmaceutical companies forecast, 2007-2012
  • Table 66: Top 117 products by global pharmaceutical sales, 2005-2007
  • Table 67: Top 61 companies by global pharmaceutical sales, 2005-2007
Promotional Video:
Back to Top